Visterra Inc. made a splash at this year's Interscience Conference on Antimicrobial Agents and Chemotherapy. The company has developed an antibody, VIS410, that neutralizes a broad spectrum of influenza A strains in a preclinical animal model. (See BioWorld Today, Sept. 12, 2012.)